FDAhigh impact
FDA PDUFA: Biohaven Troriluzole
·TBD
FDA decision on troriluzole for spinocerebellar ataxia. First potential treatment for this rare disease.
2 weeks
FDA decision on troriluzole for spinocerebellar ataxia. First potential treatment for this rare disease.
BHVN next earnings date is February 28, 2026.
Get alerts before earnings, FDA decisions, and market-moving events.
Get Early Access